Prospects for a genomic approach to the treatment of alcoholism

Archives of General Psychiatry

Volumn 65, Issue 2, 2008, Pages 132-133

  O'Brien, Charles P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BETA ENDORPHIN; DOPAMINE; MU OPIATE RECEPTOR; NALTREXONE; OPIATE RECEPTOR;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOLISM; ALLELE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; DRUG SPECIFICITY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GENOMICS; GENOTYPE; HUMAN; NONHUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; TREATMENT RESPONSE;

ALCOHOLISM; ALLELES; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENETIC MARKERS; GENOMICS; HUMANS; MACACA MULATTA; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; RECEPTORS, OPIOID, MU;

EID: 38949189294     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2007.32     Document Type: Note

References (16)

1. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Arch Gen Psychiatry. 2008;65(2):135-144.
2. Altshuler HL, Phillips PA, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26(9):679-688.
3. Volpicelli JR, O'Brien CP, Alterman AI, Hayashida M. Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LB, ed. Opioids, Bulimia, Alcohol Abuse and Alcoholism. New York, NY: Springer-Verlag; 1990:195-214.
4. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-880.
5. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881-887.
6. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18(24):10663-10671.
7. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152(4):613-615.
8. King AC, Volpicelli J, Frazer A, O'Brien C. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl). 1997;129(1):15-22.
9. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26(6):610-625.
10. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10(3):258-268.
11. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry. 1996;53(3):250-257.
12. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-1795.
13. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069-1077.
14. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546-1552.
15. Hyman SE. Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci. 2007;8(9):725-732.
16. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007;31(4):555-563.